<div id="readability-page-1"><p>Alliance Global Partners analyst James Molloy reiterated a Buy rating on Reviva Pharmaceuticals Holdings on November 14 and set a price target of $16.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Talphera, and Imunon. According to TipRanks, Molloy has an average return of <span>-26.0%</span> and a 23.12% success rate on recommended stocks. </p> <p>Reviva Pharmaceuticals Holdings has an analyst consensus of Strong Buy, with a price target consensus of $5.14.</p></div>

RVPH

<p>Alliance Global Partners analyst James Molloy reiterated a Buy rating for Reviva Pharmaceuticals Holdings, setting a price target of $16.00. Molloy, who covers the Healthcare sector, has an average return of -26.0% and a 23.12% success rate on recommended stocks. Reviva Pharmaceuticals Holdings has a consensus Strong Buy rating with a price target of $5.14.</p>

Alliance Global Partners Sticks to Their Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)